Novo Nordisk
was the first company to make a GLP-1 drug for weight loss and became Europe’s most valuable company.
But its troubles are stacking up and today the stock trades at just a quarter of what it did at its peak less than two years ago.
Pricing pressure, fierce competition, and pipeline setbacks have all hit the Danish drugmaker in recent months.
Despite being first to launch a GLP-1 drug for weight loss, Novo’s market share has eroded, and the company now only captures about 40% of the market, while rival Eli Lilly holds 60%, according to most estimates.
